In This Article:
SHANGHAI, April 14, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has received five awards at the 2025 Asia-Pacific Biopharma Excellence Awards (ABEA) ceremony. This also marks the seventh time that the company has been recognized by the organizer.
-
Best Contract Development and Manufacturing Organization Award
-
Best Aseptic Fill-Finish & Packaging CMO of the Year
-
Best Aseptic Fill-Finish & Packaging Supplier Award: Drug Delivery Systems
-
Best New Modalities Manufacturing Company
-
Best Bioprocessing Supplier Award: Cell Line Development & Characterization
WuXi Biologics is committed to advancing integrated technology platforms that accelerate biologics discovery, development, and manufacturing. It has one of the largest portfolios of complex biologics in the industry, including 151 bispecifics & multispecifics, 194 ADCs, 80 fusion proteins and 24 vaccines.The development time for monoclonal antibody projects from DNA to Investigational New Drug (IND) application has been shortened to 9 months, with a recent autoimmune disease project completed in just 6 months. By leveraging single-use technology (SUT), the company scaled manufacturing from 4,000 to 16,000 liters across its global facilities, achieving a 99% success rate (2022-2024). Given the equivalent scale, the SUT manufacturing costs are comparable to those of stainless steel systems. These milestones are underpinned by its world-class quality systems, which have ensured a 100% success rate in Pre-License Inspections (PLI) and have passed 42 inspections by global regulatory agencies, including 22 conducted by the U.S. FDA and EMA.
WuXi Biologics' high-yielding mammalian cell line platform WuXia™ (up to about 11 g/L) has been widely accepted in the industry and regulatory agencies worldwide. It has generated over 900 cell lines expressing monoclonal and bispecific antibodies, fusion proteins, enzymes and other recombinant proteins for clinical and commercial manufacturing. It has also launched WuXiaADCC Plus™, a superior-performing and high-yielding mammalian cell line platform for the development and manufacturing of afucosylated antibodies to elicit an enhanced ADCC response, and WuXia RidGS™, a high-yield glutamine synthetase (GS)-knockout CHO expression system, catering to the diverse needs of global clients.
WuXi Biologics delivers advanced drug product (DP) development services for biologics, vaccines and small molecule parenterals. Its capabilities include the development of liquid, frozen, and lyophlized dosage forms, complemented by proficiency in diverse container closure systems (CCS) that include vials and combination products such as pre-filled syringes (PFS), PFS with needle safety devices (NSD) and autoinjectors. Furthermore, the company operates multiple state-of-the-art DP manufacturing facilities for the formulation, filling, labelling, and packaging of biotherapeutics, vaccines, placebo and parenterals filled into either liquid or lyophilized dosage forms.